HB 1545 creates two new statutory sections focused on Parkinson’s disease at the University of South Florida. First, it establishes the Consortium for Parkinson’s Disease Research, made up of public and private universities and academic medical centers, and creates a Parkinson’s Disease Research Board to oversee it. The board is responsible for directing the consortium’s operations, adopting an annual research plan, and ensuring the consortium pursues scientific research on the causes, mechanisms, treatments, and prevalence of Parkinson’s disease, including among first responders. The consortium director is tasked with proposing budgets, coordinating researchers and institutions, prioritizing research, preparing plans, and seeking grants.
Second, the bill creates the Florida Institute for Parkinson’s Disease within USF as a statewide resource for research and clinical care. The institute’s stated purpose is to find a cure for Parkinson’s disease and improve quality of life and health outcomes through research, clinical care, education, and advocacy. The board must also issue an annual report to the Governor and legislative leaders by October 15 detailing research projects, findings, outreach, and future plans. The act takes effect July 1, 2025, and its implementation is contingent on available funding in the General Appropriations Act.
The bill adds new sections to chapter 1004, Florida Statutes, creating a formal state-supported Parkinson’s disease research structure at the University of South Florida. It establishes governance, reporting, and funding mechanisms for a statewide research consortium and institute, while making clear that the program operates only to the extent appropriations are provided in the annual budget. The measure affects USF, participating universities and academic medical centers, researchers, and potentially patients and first responders who may benefit from expanded research and clinical coordination.
The bill appears broadly supportive and noncontroversial in tone, with the Legislature expressly finding that Parkinson’s disease is a serious progressive neurological disorder and that innovative research is needed because there is no cure. The absence of recorded committee transcript debate or votes suggests no visible public opposition in the provided materials. Overall, the measure reflects a positive, research-oriented consensus around advancing treatment and care for Parkinson’s disease.
The main practical point of contention is likely funding, because the bill’s provisions are expressly subject to available appropriations in the General Appropriations Act. Another possible issue is governance and institutional control, since the consortium is housed at USF but includes multiple public and private universities and academic medical centers, with board membership tied to participating institutions. The bill also specifically directs research attention to Parkinson’s disease prevalence in first responders, which may reflect a targeted policy priority but is not presented in the materials as a disputed issue.